SCYNEXIS Research and Development Expenses 2013-2024 | SCYX

SCYNEXIS research and development expenses from 2013 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

SCYNEXIS Research and Development Expenses 2013-2024 | SCYX

SCYNEXIS research and development expenses from 2013 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.3B
Takeda Pharmaceutical (TAK)$46.6B
Merck (MKGAF)$23B
Astellas Pharma (ALPMY)$21.6B
Sandoz Group AG (SDZNY)$18.1B
Summit Therapeutics (SMMT)$16.5B
United Therapeutics (UTHR)$15.9B
Shionogi (SGIOY)$13.3B
Neurocrine Biosciences (NBIX)$11.7B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$7.7B
Revolution Medicines (RVMD)$7.3B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$6B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$4.6B
Corcept Therapeutics (CORT)$4.5B
Crinetics Pharmaceuticals (CRNX)$4B
Dyne Therapeutics (DYN)$3.5B
PTC Therapeutics (PTCT)$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Arrowhead Pharmaceuticals (ARWR)$2.4B
Catalyst Pharmaceuticals (CPRX)$2.4B
Recursion Pharmaceuticals (RXRX)$2B
Soleno Therapeutics (SLNO)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Xencor (XNCR)$1.6B
Harrow (HROW)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Cassava Sciences (SAVA)$1.5B